2RZ Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Poseida Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.25 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$1.71 |
| Beta | 0.51 |
| 11 Month Change | -15.04% |
| 3 Month Change | -26.15% |
| 1 Year Change | 11.29% |
| 33 Year Change | -58.75% |
| 5 Year Change | n/a |
| Change since IPO | -80.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2RZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -1.0% | 0.6% |
| 1Y | 11.3% | -13.8% | 11.8% |
Return vs Industry: 2RZ exceeded the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: 2RZ matched the German Market which returned 11.8% over the past year.
Price Volatility
| 2RZ volatility | |
|---|---|
| 2RZ Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2RZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2RZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 337 | Kristin Yarema | poseida.com |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Poseida Therapeutics, Inc. Fundamentals Summary
| 2RZ fundamental statistics | |
|---|---|
| Market cap | €219.38m |
| Earnings (TTM) | -€103.13m |
| Revenue (TTM) | €80.90m |
2.8x
P/S Ratio-2.2x
P/E RatioIs 2RZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2RZ income statement (TTM) | |
|---|---|
| Revenue | US$88.46m |
| Cost of Revenue | US$156.78m |
| Gross Profit | -US$68.32m |
| Other Expenses | US$44.46m |
| Earnings | -US$112.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -77.23% |
| Net Profit Margin | -127.48% |
| Debt/Equity Ratio | 96.7% |
How did 2RZ perform over the long term?
See historical performance and comparison